mTOR inhibition: a double-edged sword in patients with COVID-19?

The current COVID-19 is one of the deadliest pandemics in recent decades. In the lack of a specific treatment for this novel infection, knowing the role of cell signaling pathways in the pathogenesis of this infection could be useful in finding effective drugs against this disease. The mammalian or...

Full description

Saved in:
Bibliographic Details
Published inHuman cell : official journal of Human Cell Research Society Vol. 34; no. 2; pp. 698 - 699
Main Author Ghasemnejad-Berenji, Morteza
Format Journal Article
LanguageEnglish
Published Singapore Springer Singapore 01.03.2021
Springer Nature B.V
Subjects
Biomedical and Life Sciences
Cell Biology
Commentary
Coronaviruses
COVID-19
COVID-19 - drug therapy
COVID-19 - immunology
Drug Repositioning
Gynecology
Humans
Immune system
Immune System - immunology
Immunosuppressive agents
Infections
Life Sciences
Oncology
Pandemics
Protein biosynthesis
Protein turnover
Rapamycin
Reproductive Medicine
Severe acute respiratory syndrome coronavirus 2
Signal transduction
Signal Transduction - genetics
Signal Transduction - physiology
Sirolimus - pharmacology
Sirolimus - therapeutic use
Stem Cells
Surgery
TOR protein
TOR Serine-Threonine Kinases - antagonists & inhibitors
TOR Serine-Threonine Kinases - physiology
COVID-19
mTOR
SARS-CoV-2
Rapamycin
Cell signaling
Immune system
Online AccessGet full text

Cover

More Information
Summary:The current COVID-19 is one of the deadliest pandemics in recent decades. In the lack of a specific treatment for this novel infection, knowing the role of cell signaling pathways in the pathogenesis of this infection could be useful in finding effective drugs against this disease. The mammalian or mechanistic target of rapamycin (mTOR) is an important cell signaling pathway that has important role in the regulation of cell growth, protein synthesis, and metabolism in reactance to upstream signals in both pathological and normal physiological conditions. Recently, some researchers have suggested the therapeutic potential of mTOR inhibitors such as rapamycin against COVID‐19. However, it is important to consider the role of activation of this pathway in controlling immune system response against viral activity in drug repositioning of rapamycin and other mTOR inhibitors in SARS-CoV-2 infection.
ISSN:1749-0774
0914-7470
1749-0774
DOI:10.1007/s13577-021-00495-2